Targos – Professional expertise for biomarker development
To our Valued Customers, Partners and Suppliers:
Targos is closely monitoring the coronavirus (COVID-19) outbreak and has already taken all necessary measures in accordance to the recommended pandemia plan in the beginning of March. As we strictly follow this pandemia plan in order to ensure the protection and safety of our employees, customers, partners and suppliers, we are able to prevent spread of the infection within the company once an employee should be infected. Our team is very well prepared and continues to work in all aspects of our service portfolio, including central testing, assay validation and biomarker training. All incoming samples are currently analyzed with the same speed and diligence as usual. Our suppliers keep on providing us with essential reagents, which continue to ensure analyses in the ongoing clinical trials.
The Targos Advance Biomarker training courses for PD-L1 and Her2 applications have been successfully switched to a virtual format avoiding personal contacts. Please contact us for additional information at email@example.com.
Thank you for your continued support.
Yours sincerely, Thomas Henkel CEO
The One Health Initiative:
The “One Health initiative” www.onehealthinitiative.com fosters close interactions between physicians and veterinarians with the goal to further investigate neoplastic, nutritional and metabolic diseases, environmental health threats and zoonotic diseases.
Image: Brain of a rabbit with meningoencephalitis.
Targos & Ultivue
Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services.
Research and experience of Targos staff
- Published by Springer
20. February 2019
Targos is proud to present the new comprehensive Springer Nature publication Predictive Biomarkers in Oncology. Applications in Precision Medicine- edited by Sunil Badve, Indiana University and George Kumar, Targos Inc, co-authored by many international experts from academic, clinical, government (FDA, NCI), and industry background: demonstrating our network and expertise.
Philips & Targos
Royal Philips (NYSE: PHG, AEX: PHIA) and Targos, today announced a joint initiative to enhance digital pathology education and help drive the global standardization of clinical biomarkers.
31st European Congress of Pathology
- Pathology is Nice
1. Standardised structured training of pathologists to improve inter- and intra-reader reproducibility for scoring PD-L1 expression levels in non-small cell lung cancer: results of a worldwide training programme.
2. Digital microscopy - is there a need for standardisation?
3. High reproducibility of PD-L1 scoring among pathologists participating in live trainings.
Prof. Reinhard Büttner:
• Genomic profiling for driver mutations in cancer: NTRK gene fusions (Bayer)
• LS-09 From respectable to exceptional: advancing beyond existing PD-L1 test capabilities for histologic and cytologic NSCLC specimens (AstraZeneca)
Prof. Bharat Jasani:
• Strategies for addressing the intrinsic source of error associated with PD-L1 scoring and interpretation.
PD-L1 training & testing
In addition, we also provide PD-L1 testing services within clinical trials utilizing currently commercially available PD-L1 IVD assays (SP142, SP263, 22C3, 28-8) validated in a fully CAP/CLIA compliant environment.
TARGOS Molecular Pathology GmbH
+49 561-50045299 +49 561-50045355 firstname.lastname@example.org